

CURRICULUM VITAE

Pr Abde-Rahmene AZZOUZI

Nationality : French

Medical and Research Curriculum

- October 1985 – October 1993 : Medical School – Faculty of Medicine X. Bichat (Paris Diderot University)
- November 1993 - October 1998 : **Resident at Nancy Teaching Hospital (Urology Speciality)**
- November 1998 - October 1999 : Master's Science in Surgical Sciences (Paris Saclay University)
Subject: "Pathological and genetic analysis of latent prostate cancer "
Director: Professor Olivier CUSSENOT (Laboratoire: CeRePP)
- November 1999 - November 2003 : **PhD degree**
Subject: « Genetic Risk Factors of Prostatic Tumours »
Director: Professeur Olivier CUSSENOT
Laboratory: CeRePP-UA3104 Paris Diderot University
- November 1999 - October 2001 : **Chief Resident in Urology**
Department of Urology – Brabois Teaching Hospital - Nancy (Professor P. MANGIN)
- November 2001 - December 2001 : **Consultant** Department of Urology – Brabois Teaching Hospital - Nancy
- January 2002 - December 2002 : **Clinical Research Fellow**
Academic Urology Unit – Royal Hallamshire Hospital
University of Sheffield – United Kingdom
- January 2003 - September 2004 : **Clinical Senior Lecturer – Honorary Consultant Surgeon**
Academic Urology Unit – Royal Hallamshire Hospital
University of Sheffield – United Kingdom
- November 2004 – September 2005 : **Consultant Urological Surgeon**
Department of Urology – La Pitié-Salpêtrière Hospital
- October 2005- September 2010 : **Clinical Senior Lecturer – Consultant Surgeon**
Department of Urology – University of Angers, France
Department of Radiotherapy – Institut de Cancérologie de l'Ouest, Angers
- May 2008 – July 2018 : **Head of Departement**
Department of Urology – University of Angers, France
- Since September 2010 : **University Professor – Consultant Surgeon**
Department of Urology – University of Angers, France
Department of Radiotherapy – Institut de Cancérologie de l'Ouest, Angers
- Since September 2016 : **Consultant Uro-Oncologist**
Department of Urology – University of Angers, France

Academic qualifications

- **Certificate of MMedSci of Molecular Biology** NANCY 1996
- **Medical Degree** NANCY 1999
Subject: "Familial prostate cancer undergoing radical prostatectomy do not show any specific aggressiveness when compared sporadic cases "
Director: Doctor Antoine VALERI
- **Certificate of MMedSci of Biology** PARIS 1999
Molecular Biology and Genetic (Paris Diderot University)
- **Master's Science in Surgical Sciences** (cancerology option) PARIS 1999
Subject: "Pathological and genetic analysis of latent prostate cancer "
Director: Professor Olivier CUSSENOT
- **Interuniversity degree** (Medical Teaching and Echography) NANCY 2001
- **PhD degree (cancerology option)** PARIS 2003
Subject: « Genetic Risk Factors of Prostatic Tumours »
- **University Degree in Laparoscopy** - IRCADÉ - STRASBOURG 2005
- **Head of Urology Chair** Angers 2006-2018
- **Expert for the IMI Program** since 2017 European Commission BRUXELLES

Most relevant publications

1. Valeri A., **Azzouzi R.**, Drelon E. et al. Early onset hereditary prostate cancer is not associated with specific clinical and biological features. *The Prostate*, 2000, 45: 66-71.
2. Latil A., **Azzouzi R.**, Cancel G., Guillaume E. et al. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. *Cancer*. 2001 Sep 1; 92(5):1130-7.
3. **Azzouzi A.R.**, Cochand-Priollet B, Mangin Ph et al. Impact of constitutional genetic variation in androgen/oestrogen regulating genes on age related changes in human prostate. *European Journal of Endocrinology* 2002 147:1-6
4. **Azzouzi A.R.**, Valeri A., Cormier L. et al. Familial prostate cancer undergoing radical prostatectomy do not show any specific aggressiveness when compared sporadic cases. *Urology* 2003 Jun; 61:1193-1197.
5. Rehman I, **Azzouzi A.R.**, Cross SS et al. Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions. *Hum Pathol*. 2004 Nov;35(11):1385-91
6. I. Rehman, **R. Azzouzi**, J.W.F Catto et al. Proteomic analysis of voided urine following prostatic massage from prostate cancer patients: A pilot study. *Urology* 2004 Dec;64(6):1238-43
7. J.W.F. Catto, **A.R. Azzouzi**, I. Rehman et al. The epigenetic and genetic alterations in transitional cell carcinoma differ with anatomical location and are associated with tumour behaviour. *J Clin Oncol*. 2005 May;23(13):2903-10
8. **Azzouzi A.R.**, Catto J.W.F., Rehman I. et al. Clinically localised prostate cancer is microsatellite stable. *BJU Int*. 2007 May;99(5):1031-5.
9. **Azzouzi A.R.**, Stoppa-Lyonnet D., Roupret M. et al. BRCA2 mutations screening is clinically relevant in breast and early prostate cancer families. *Int J Urol*. 2007 May;14(5):445-6.
10. Cussenot O, **Azzouzi A.R.**, Nicolaiew N et al. Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens. *J Clin Oncol*. 2007 Aug 20;25(24):3596-602.
11. Cussenot O., **Azzouzi A.R.**, Nicolaiew N. et al. Low activity V89L polymorphism in SRD5A2 gene is associated to aggressive prostate cancer risk. A model to discuss controversies aroused by chemoprevention trials using 5-a-reductase inhibitors. *Eur Urol* 2007 Oct;52(4):1082-7.
12. Cussenot O, **Azzouzi AR**, Bantsimba-Malanda G et al. Effect of genetic variability within 8q24 on aggressiveness patterns at diagnosis and familial status of prostate cancer. *Clin Cancer Res*. 2008 Sep 1;14(17):5635-9.
13. Lebdai S, Bigot P, **Azzouzi AR**. High-grade prostate cancer and finasteride. *BJU Int*. 2010 Feb;105(4):456-9
14. Azzouzi A.R., Barret E., Moore C.M et al. **TOOKAD® Soluble Vascular Targeted Photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.** *BJU Int*. 2013 Oct;112(6):766-74.
15. Moore CM, **Azzouzi AR**, Barret E et al. Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localized prostate cancer using WST11-Vascular Targeted Photodynamic (VTP) therapy. *BJU Int*. 2014 May 19. doi: 10.1111/bju.12816.
16. **Azzouzi AR**, Barret E, Bennet J et al. **TOOKAD® Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer.** *World J Urol*. 2015 Jul;33(7):945-53.
17. **Azzouzi AR**, Lebdai S, Benzaghoul F, Stief C. **Vascular-targeted photodynamic therapy with **TOOKAD® Soluble** in localized prostate cancer: standardization of the procedure.** *World J Urol*. 2015 Jul;33(7):937-44.
18. Lebdai S, Villers A, Barret E, Nedelcu C, Bigot P, **Azzouzi AR**. **Feasibility, safety, and efficacy of salvage radical prostatectomy after Tookad(®) Soluble focal treatment for localized prostate cancer.** *World J Urol*. 2015 Jul;33(7):965-71.
19. **Azzouzi AR**, Vincendeau S, Barret E et al. **PCM301 Study Group. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.** *Lancet Oncol*. 2017 Feb;18(2):181-191
20. Lebdai S, Bigot P, Leroux PA, Berthelot LP, Maulaz P, **Azzouzi AR**. **Vascular-Targeted Photodynamic Therapy with Padeliporfin for Low Risk Prostate Cancer Treatment: Mid-Term Oncological Outcomes.** *J Urol*. 2017 Mar 18.

Scientific Awards

2002	AUA Gerald Murphy Scholar Award to the most promising academic Urologists (97th American Urological Association Congress - Orlando - USA)
2004	Best Presentation On Oncological Urology (XIXth Congress of the European Association of Urology - Stockholm - Sweden)
2019	Tayyaba Hasan IMPACT Award 17th World Congress of the International Photodynamic Association (Harvard Medical School – Boston - USA)

Prostate Photodynamic Therapy-related scientific publications

1. Eymerit-Morin C, Zidane M, Lebdaï S, Triau S, **Azzouzi AR**, Rousselet MC. Histopathology of prostate tissue after vascular-targeted photodynamic therapy for localized prostate cancer. *Virchows Arch*. 2013 Oct;463(4):547-52.
2. **Azzouzi AR**, Barret E, Moore CM, Villers A, Allen C, Scherz A, Muir G, de Wildt M, Barber NJ, Lebdaï S, Emberton M. **TOOKAD®** Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer. *BJU Int*. 2013 Oct;112(6):766-74.
3. Kulik M, Nedelcu C, Martin F, Lebdaï S, Rousselet MC, **Azzouzi AR**, Aubé C. Post-treatment MRI aspects of photodynamic therapy for prostate cancer. *Insights Imaging*. 2014 Dec;5(6):697-713.
4. Lebdaï S, Martin F, Bigot P, **Azzouzi AR**. [Treatment of localized prostate cancer by vascular-targeted photodynamic therapy with WST11]. *Prog Urol*. 2014 Nov;24(14):911-4.
6. **Azzouzi AR**, Lebdaï S, Benzaghrou F, Stief C. Vascular-targeted photodynamic therapy with **TOOKAD®** Soluble in localized prostate cancer: standardization of the procedure. *World J Urol*. 2015 Jul;33(7):937-44.
7. Lebdaï S, Villers A, Barret E, Nedelcu C, Bigot P, **Azzouzi AR**. Feasibility, safety, and efficacy of salvage radical prostatectomy after Tookad® Soluble focal treatment for localized prostate cancer. *World J Urol*. 2015 Jul;33(7):965-71.
8. Moore CM, **Azzouzi AR**, Barret E, Villers A, Muir GH, Barber NJ, Bott S, Trachtenberg J, Arumainayagam N, Gaillac B, Allen C, Schertz A, Emberton M. Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy. *BJU Int*. 2015 Dec;116(6):888-96.
9. **Azzouzi AR**, Barret E, Bennet J, Moore C, Taneja S, Muir G, Villers A, Coleman J, Allen C, Scherz A, Emberton M. **TOOKAD®** Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer. *World J Urol*. 2015 Jul;33(7):945-53.
10. **Azzouzi AR**, Vincendeau S, Barret E, Cicco A, Kleinclaus F, van der Poel HG, Stief CG, Rassweiler J, Salomon G, Solsona E, Alcaraz A, Tammela TT, Rosario DJ, Gomez-Veiga F, Ahlgren G, Benzaghrou F, Gaillac B, Amzal B, Debryne FM, Fromont G, Gratzke C, Emberton M; PCM301 Study Group. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. *Lancet Oncol*. 2017 Feb;18(2):181-191.
12. Taneja SS, Bennett J, Coleman J, Grubb R, Andriole G, Reiter RE, Marks L, **Azzouzi AR**, Emberton M. Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States. *J Urol*. 2016 Oct;196(4):1096-104. doi: 10.1016/j.juro.2016.05.113.
13. Lebdaï S, Lunelli L, Bigot P, Cussenot O, **Azzouzi AR**. [Focal therapies: An alternative option for low-risk prostate cancer management?]. *Presse Med*. 2017 Oct;46(10):935-939.
14. **Azzouzi AR**, Emberton M; PCM301 study investigators. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer - Authors' reply. *Lancet Oncol*. 2017 Apr;18(4):e188.
15. Lebdaï S, Bigot P, Leroux PA, Berthelot LP, Maulaz P, **Azzouzi AR**. Vascular Targeted Photodynamic Therapy with Padeliporfin for Low Risk Prostate Cancer Treatment: Midterm Oncologic Outcomes. *J Urol*. 2017 Aug;198(2):335-344.
16. Rodriguez-Rivera JA, Rodriguez-Lay R, Zegarra-Montes L, Benzaghrou F, Gaillac B, **Azzouzi AR**, Reis LO, Palma P. Expanding indication of padeliporfin (WST11) vascular-targeted photodynamic therapy: results of prostate cancer Latin-American multicenter study. *Actas Urol Esp*. 2018 Dec;42(10):632-638.
17. Noweski A, Roosen A, Lebdaï S, Barret E, Emberton M, Benzaghrou F, Apfelbeck M, Gaillac B, Gratzke C, Stief C, **Azzouzi AR**. Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using **TOOKAD** Soluble WST-11 (Phase II Trials). *Eur Urol Focus*. 2019 Nov;5(6):1022-1028.
18. Gill IS, **Azzouzi AR**, Emberton M, Coleman JA, Coeytaux E, Scherz A, Scardino PT; PCM301 Study Group. Randomized Trial of Partial Gland Ablation with Vascular Targeted Phototherapy versus Active Surveillance for Low Risk Prostate Cancer: Extended Followup and Analyses of Effectiveness. *J Urol*. 2018 Oct;200(4):786-793.
19. Pierrard V, Lebdaï S, Kleinclaus F, **Azzouzi AR**, Terrier JE, Fortier E, Joniau S, Van Der Poel H, Salomon G, Casanova J, Medina-Lopez RA, Potiron E, Rigaud J, Vincendeau S, Rassweiler J, Villers A, Gaston R, Saussine C, Giai J, Gaillac B, Emberton M, Ruffion A. Radical Prostatectomy after Vascular Targeted Photodynamic Therapy with Padeliporfin: Feasibility, and Early and Intermediate Results. *J Urol*. 2019 Feb;201(2):315-321.
20. Lebdaï S, Gigoux M, Alvim R, Somma A, Nagar K, **Azzouzi AR**, Cussenot O, Merghoub T, Wolchok JD, Scherz A, Kim K, Coleman J. Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation of myeloid cells in a preclinical model of prostate cancer. *Oncoimmunology*. 2019 Mar 28;8(6):e1581528.
21. Chelly S, Maulaz P, Bigot P, **Azzouzi AR**, Lebdaï S. Erectile function after WST11 vascular-targeted photodynamic therapy for low-risk prostate cancer treatment. *Asian J Androl*. 2020 Sep-Oct;22(5):454-458.